$120.59+23.51% · 3M
Moving avg
1W+0.02%
1M+4.77%
3M+26.52%
6M+19.27%
YTD+18.90%
1Y+39.95%
3Y+84.83%
5Y+62.97%
52-week range
$69.69100% of range$119.60
Company health
Value3/6
Growth6/6
Profitability6/6
Health6/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Strong 25% net margin
- High return on equity (2931%)
- Revenue compounding 23% a year
- Net cash on the balance sheet
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$24.44B
Enterprise value
$20.08B
P/E ratio (TTM)
16.12x
P/S ratio (TTM)
4.39x
EV/EBITDA
10.73x
Per share & returns
EPS (TTM)
$7.18
Dividend yield
0.00%
Beta (1Y)
0.76
30-day change
+4.77%
Trading
Volume (24h)
248.82K
Previous close
$120.77
Shares outstanding
202.70M
About Incyte Corporation
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
INCY
Incyte Corporation is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker INCY.
Frequently asked questions
What is Incyte Corporation's market cap?
Incyte Corporation (INCY) has a market capitalization of $24.44B.
What is Incyte Corporation's P/E ratio?
Incyte Corporation trades at a price-to-earnings (P/E) ratio of 16.12.
What exchange does INCY trade on?
INCY trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,218.39-0.15%
$1.15T cap
Johnson & JohnsonJNJ
$261.39+0.20%
$629.92B cap
AbbVie Inc.ABBV
$250.32+0.63%
$442.26B cap
UnitedHealth Group IncorporatedUNH
$402.17-0.84%
$365.22B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.77+1.39%
$332.86B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.76B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap